Societal cost of oropharyngeal cancer by human papillomavirus status, cancer stage, and subsite.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
03
2019
accepted:
17
07
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
4
3
2020
Statut:
epublish
Résumé
The incidence of oropharyngeal cancer (OPC) is increasing, particularly human papillomavirus (HPV)-associated OPC. The aim of this study was to specify the total societal cost of OPC by HPV status, cancer stage, and subsite using a bottom-up cost-of-illness approach. We analyzed 121 consecutive patients with OPC from the Southern Health Care Region of Sweden. We estimated the direct medical costs and indirect costs (e.g., disease-related morbidity and premature death) from 1 month prior to OPC diagnosis until 3 years after treatment completion. The mean total cost per patient was €103 386 for HPV-positive and €120 244 for HPV-negative OPC. Eighty-one percent of the patients analyzed were HPV-positive: Accordingly, HPV-positive OPC represented 79% of the total cost of OPC. The mean total cost of stage I, II, III, IVA, IVB, and IVC, regardless of HPV status, was €59 424, €57 000, €69 246, €115 770, €234 459, and €21 930, respectively, of which indirect costs were estimated at €22 493 (37.8%), €14 754 (25.9%), €28 681 (41.4%), €67 107 (58%), €166 280 (70.9%), and €0. Tonsillar cancer represented 64% of OPC, with a mean total cost of €117 512 per patient. The societal cost of OPC is substantial. HPV-associated OPC comprises 79% of the total cost of this disease. The data presented in this study may be used in analytical models to aid decision makers in determining the potential value of gender-neutral HPV vaccination.
Sections du résumé
BACKGROUND
The incidence of oropharyngeal cancer (OPC) is increasing, particularly human papillomavirus (HPV)-associated OPC. The aim of this study was to specify the total societal cost of OPC by HPV status, cancer stage, and subsite using a bottom-up cost-of-illness approach.
METHODS
We analyzed 121 consecutive patients with OPC from the Southern Health Care Region of Sweden. We estimated the direct medical costs and indirect costs (e.g., disease-related morbidity and premature death) from 1 month prior to OPC diagnosis until 3 years after treatment completion.
RESULTS
The mean total cost per patient was €103 386 for HPV-positive and €120 244 for HPV-negative OPC. Eighty-one percent of the patients analyzed were HPV-positive: Accordingly, HPV-positive OPC represented 79% of the total cost of OPC. The mean total cost of stage I, II, III, IVA, IVB, and IVC, regardless of HPV status, was €59 424, €57 000, €69 246, €115 770, €234 459, and €21 930, respectively, of which indirect costs were estimated at €22 493 (37.8%), €14 754 (25.9%), €28 681 (41.4%), €67 107 (58%), €166 280 (70.9%), and €0. Tonsillar cancer represented 64% of OPC, with a mean total cost of €117 512 per patient.
CONCLUSION
The societal cost of OPC is substantial. HPV-associated OPC comprises 79% of the total cost of this disease. The data presented in this study may be used in analytical models to aid decision makers in determining the potential value of gender-neutral HPV vaccination.
Identifiants
pubmed: 31356646
doi: 10.1371/journal.pone.0220534
pii: PONE-D-19-08166
pmc: PMC6663066
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220534Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pharmacoeconomics. 1998 Jan;13(1 Pt 1):1-7
pubmed: 10175982
J Clin Pathol. 2006 May;59(5):445-53
pubmed: 16644882
Radiother Oncol. 2007 Jul;84(1):5-10
pubmed: 17493700
BMJ. 2011 Sep 27;343:d5775
pubmed: 21951758
Head Neck Oncol. 2011 Oct 28;3:47
pubmed: 22035422
Vaccine. 2012 Sep 14;30(42):6016-9
pubmed: 22867718
Br J Cancer. 2014 Mar 18;110(6):1587-94
pubmed: 24518594
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Otolaryngol Head Neck Surg. 2015 Nov;153(5):758-69
pubmed: 26124261
Laryngoscope. 2017 Oct;127(10):2270-2278
pubmed: 28304083
PLoS One. 2017 Jun 26;12(6):e0179520
pubmed: 28651012
Clin Otolaryngol. 2018 Feb;43(1):223-229
pubmed: 28734109
Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1443-1449
pubmed: 28838945
Am J Public Health Nations Health. 1967 Mar;57(3):424-40
pubmed: 6066903
Med Care. 1996 Dec;34(12 Suppl):DS197-9
pubmed: 8969326